Analysts Offer Insights on Healthcare Companies: Prestige Consumer Healthcare (PBH) and Vericel (VCEL)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Prestige Consumer Healthcare (PBH – Research Report) and Vericel (VCEL – Research Report) with bullish sentiments.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Prestige Consumer Healthcare (PBH)
In a report released today, Susan Anderson from Canaccord Genuity reiterated a Buy rating on Prestige Consumer Healthcare, with a price target of $88.00. The company’s shares closed last Tuesday at $64.70, close to its 52-week low of $62.35.
According to TipRanks.com, Anderson is a 5-star analyst with an average return of
Prestige Consumer Healthcare has an analyst consensus of Strong Buy, with a price target consensus of $79.50, a 22.1% upside from current levels. In a report released yesterday, William Blair also maintained a Buy rating on the stock.
See today’s best-performing stocks on TipRanks >>
Vericel (VCEL)
In a report released today, Richard Newitter from Truist Financial maintained a Buy rating on Vericel. The company’s shares closed last Tuesday at $37.05.
According to TipRanks.com, Newitter is a 5-star analyst with an average return of
Currently, the analyst consensus on Vericel is a Strong Buy with an average price target of $57.67, a 53.6% upside from current levels. In a report released yesterday, TD Cowen also reiterated a Buy rating on the stock with a $55.00 price target.
